Radcliffe Capital Management’s DA32 Life Science Tech Acquisition Corp DALS Stock Holding History
Bought
Maintained
Sold
Radcliffe Capital Management's DALS Position: Q3 2023 in Review
Radcliffe Capital Management sold out of DA32 Life Science Tech Acquisition Corp (DALS) in Q3 2023, closing a stake of 165,205 shares — an estimated $1.7M sold.
Radcliffe Capital Management first reported a position in DALS in Q1 2022 and held it in 6 quarters. The position peaked at $1.7M in Q2 2023. 0 funds tracked by Wall St. Rank hold DALS as of Q3 2023.
- Radcliffe Capital Management reported no remaining DA32 Life Science Tech Acquisition Corp position as of Q3 2023 after selling out during the quarter.
- Radcliffe Capital Management sold 165,205 DA32 Life Science Tech Acquisition Corp shares in Q3 2023, an estimated $1.7M.
- Radcliffe Capital Management first reported a position in DA32 Life Science Tech Acquisition Corp in Q1 2022 and held it in 6 quarters.
- Radcliffe Capital Management's DA32 Life Science Tech Acquisition Corp position peaked at $1.7M in Q2 2023.
- 0 funds tracked by Wall St. Rank held DA32 Life Science Tech Acquisition Corp as of Q3 2023.
Based on Radcliffe Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.